SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Colorful DNA molecule. Structure of the genetic code. Genetic Syndrome and Genetic Disorder, 3D illustration of science concept.
Gene therapy
Bluebird’s Gene Therapy Skysona Under FDA Safety Probe for Hematologic Malignancies
The cancers were diagnosed 19 to 92 months after Skysona treatment.
December 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Complete response letters
Applied Therapeutics Crashes After FDA Rejection of Rare Disease Drug
After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ govorestat for galactosemia, citing “deficiencies” with the application. The biotech plans to meet with the regulator to discuss the best way forward for the drug.
December 2, 2024
 · 
3 min read
 · 
Tristan Manalac
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus will reveal promising mid-stage data for their respective cancer candidates.
December 2, 2024
 · 
4 min read
 · 
Tristan Manalac
A magical door in the forest with bright glowing lights.
Editorial
FDA’s Accelerated Approval Pathway Drives Momentum for Intractable, Fatal Diseases
Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track record of propelling R&D for some of medicine’s most challenging illnesses.
December 2, 2024
 · 
6 min read
 · 
Heather McKenzie
Hand touches AI artificial intelligence, digital data and future technology. Futurism, robot computer software, digital twin, blockchain, virtual technology.
Artificial intelligence
Digital Twins Could Augment Clinical Research, Help Ease Data Disparities
Projected to be worth over $38 billion in the global healthcare market by 2032, AI simulations have the potential to streamline clinical trials and help address inequities in underserved patient populations.
December 2, 2024
 · 
6 min read
 · 
Joanna Smiley
Cancer of the brain as tumor growth diagnosis and symptoms of gliomas meningiomas astrocytomas and oligodendrogliomas as diagnosis of symptoms as a paper sculpture.
Brain cancer
Biopharma Takes on Deadly Brain Cancer After Decades of Failure
Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics and others are targeting the often-fatal brain tumor.
December 2, 2024
 · 
7 min read
 · 
Kate Goodwin
Contemporary art collage. Conceptual design. Making financial strategy. Employees sitting on company graph, creating analytics. Way to financial growth. Concept of business, brainstorming, team
Business
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.
November 27, 2024
 · 
9 min read
 · 
Annalee Armstrong
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Neurodegenerative disease
PTC Scraps ALS Asset Utreloxastat After Mid-Stage Fail, Analysts Look to PKU Opportunity
Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect PTC, instead postulating that the upcoming FDA decision on its phenylketonuria candidate sepiapterin will be a stronger driver of the biotech’s stock.
November 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Bethesda, Maryland 09/12/2020: View of the main historical building (Building 1) of the National Institutes of Health (NIH) inside Bethesda campus. U.S. Public Health Service seal is seen on top of it
Government
Trump Picks Stanford’s Jay Bhattacharya as NIH Lead
Trump is rounding out his health cabinet with another controversial figure: one of the authors of the Great Barrington Declaration, which advocated for herd immunity through infection during the COVID-19 pandemic.
November 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS